研究单位：[1]Loxo Oncology, Inc.[2]Eli Lilly and Company[3]Genesis Cancer Center,Hot Springs,Arkansas,United States,71913[4]Pacific Cancer Medical Center, Inc,Anaheim,California,United States,92801[5]TOI Clinical Research,Cerritos,California,United States,90703[6]California Cancer Associates for Research and Excellence,San Marcos,California,United States,92069[7]Asclepes Research Centers Florida,Brooksville,Florida,United States,34613[8]Florida Cancer Specialists,Fort Myers,Florida,United States,33901[9]Cancer Specialists of North Florida -St Augustine,Jacksonville,Florida,United States,32256[10]Florida Cancer Specialists,Saint Petersburg,Florida,United States,33705[11]Florida Cancer Specialists East,West Palm Beach,Florida,United States,33401[12]Hematology Oncology Clinic,Baton Rouge,Louisiana,United States,70809[13]Tulane Cancer Center Office of Clinical Research,New Orleans,Louisiana,United States,70112[14]American Oncology Partners of Maryland, PA,Bethesda,Maryland,United States,20817[15]TidalHealth Richard A. Henson Cancer Institute,Ocean Pines,Maryland,United States,21811[16]TidalHealth Peninsula Regional, Inc.,Salisbury,Maryland,United States,21801[17]St. Vincent Frontier Cancer Center,Billings,Montana,United States,59102[18]Novant Cancer Institute Charlotte,Charlotte,North Carolina,United States,28204[19]Novant Health, Oncology Research Institute,Winston-Salem,North Carolina,United States,27103[20]Asante Rogue Regional Medical Center,Medford,Oregon,United States,97504[21]Cancer Care Associates of York,York,Pennsylvania,United States,17403[22]Sarah Cannon Research Institute SCRI,Chattanooga,Tennessee,United States,37404[23]Kelsey Research Foundation,Houston,Texas,United States,77025[24]Lumi Research,Kingwood,Texas,United States,77339[25]Virginia Cancer Institute,Richmond,Virginia,United States,23228[26]Hospital Italiano de Buenos Aires,ABB,Ciudad Autónoma De Buenos Aire,Argentina,1199[27]Clínica de Nefrología, Urología y Enfermedades Cardiovasculares,Santa Fe,Argentina,3000[28]One Clinical Research,Nedlands,Western Australia,Australia,6009[29]The Perth Blood Institute,West Perth,Australia,6005[30]VITAZ,Sint-Niklaas,Oost-Vlaanderen,Belgium,9100[31]AZ Delta,Roeselare,West Flanders,Belgium,8800[32]Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg,Leuven,Belgium,3000[33]Hospital de Clínicas de Ribeirão Preto,Ribeirão Preto,São Paulo,Brazil,14051-140[34]CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia,Santo André,São Paulo,Brazil,09060-650[35]Hospital Uopeccan - Centro de Pesquisa Clinica,Cascavel,Brazil,85806-300[36]Hopital de L'Enfant Jesus,Québec,Canada,G1J 1Z4[37]CeCim Biocinetic,Santiago,Región Metropolitana,Chile,8320000[38]Centro de Estudios Clinicos SAGA,Providencia,Santiago,Chile,7500653[39]Centro de Investigaciones Clínicas Viña del Mar (CIC),Viña del Mar,Valparaíso,Chile,2520000[40]Southern Medical University Nanfang Hospital,Guangzhou,Guangdong,China,510515[41]Wu Han Tongji Hospital,Wuhan City,Hubei,China,430030[42]Blood Institute of the Chinese Academy of Medical science,Tianjin,Tianjin,China,300020[43]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300052[44]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China,430022[45]Fakultni nemocnice Brno,Brno,Czechia,62500[46]Fakultni Nemocnice Ostrava,Ostrava-Poruba,Czechia,708 52[47]Fakultni Nemocnice Plzen,Plzen - Lochotin,Czechia,30460[48]Fakultni nemocnice Kralovske Vinohrady,Praha 10,Czechia,100 34[49]Hopital de la Pitie Salpetriere,Paris,Cedex 13,France,75651[50]CHU de Nantes - Hotel Dieu,Nantes,Cedex 1,France,44093[51]Hôpital de Pontchaillou,Rennes,Cedex 9,France,35033[52]Centre Hospitalier Lyon Sud,Pierre Benite,Cedex,France,69495[53]Centre Antoine Lacassagne,Nice,Nice Cedex 2,France,06189[54]CHRU De Tours,Tours,Tours Cedex 9,France,37044[55]CHD Vendee,La Roche sur Yon,France,85000[56]Centre Hospitalier du Mans,Le Mans,France,72000[57]Hématologie Clinique et Thérapie Cellulaire,Limog
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
